BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26183543)

  • 21. Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4.
    Haikarainen T; Venkannagari H; Narwal M; Obaji E; Lee HW; Nkizinkiko Y; Lehtiö L
    PLoS One; 2013; 8(6):e65404. PubMed ID: 23762361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tankyrases: structure, function and therapeutic implications in cancer.
    Haikarainen T; Krauss S; Lehtio L
    Curr Pharm Des; 2014; 20(41):6472-88. PubMed ID: 24975604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.
    Li B; Liang J; Lu F; Zeng G; Zhang J; Ma Y; Liu P; Wang Q; Zhou Q; Chen L
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32268564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
    Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
    Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.
    Riffell JL; Lord CJ; Ashworth A
    Nat Rev Drug Discov; 2012 Dec; 11(12):923-36. PubMed ID: 23197039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
    Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
    Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
    J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
    Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of tankyrase activity by a catalytic domain dimer interface.
    Fan C; Yarravarapu N; Chen H; Kulak O; Dasari P; Herbert J; Yamaguchi K; Lum L; Zhang X
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1780-1785. PubMed ID: 30055800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of new dual binding TNKS inhibitors of Wnt signaling inhibition by pharmacophore modeling, molecular docking and bioassay.
    Pu Y; Zhang S; Chang Z; Zhang Y; Wang D; Zhang L; Li Y; Zuo Z
    Mol Biosyst; 2017 Jan; 13(2):363-370. PubMed ID: 27995250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library.
    Samain F; Ekblad T; Mikutis G; Zhong N; Zimmermann M; Nauer A; Bajic D; Decurtins W; Scheuermann J; Brown PJ; Hall J; Gräslund S; Schüler H; Neri D; Franzini RM
    J Med Chem; 2015 Jun; 58(12):5143-9. PubMed ID: 26061013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A FRET-based high-throughput screening platform for the discovery of chemical probes targeting the scaffolding functions of human tankyrases.
    Sowa ST; Vela-Rodríguez C; Galera-Prat A; Cázares-Olivera M; Prunskaite-Hyyryläinen R; Ignatev A; Lehtiö L
    Sci Rep; 2020 Jul; 10(1):12357. PubMed ID: 32704068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tankyrase is necessary for canonical Wnt signaling during kidney development.
    Karner CM; Merkel CE; Dodge M; Ma Z; Lu J; Chen C; Lum L; Carroll TJ
    Dev Dyn; 2010 Jul; 239(7):2014-23. PubMed ID: 20549720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
    Shirai F; Mizutani A; Yashiroda Y; Tsumura T; Kano Y; Muramatsu Y; Chikada T; Yuki H; Niwa H; Sato S; Washizuka K; Koda Y; Mazaki Y; Jang MK; Yoshida H; Nagamori A; Okue M; Watanabe T; Kitamura K; Shitara E; Honma T; Umehara T; Shirouzu M; Fukami T; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2020 Apr; 63(8):4183-4204. PubMed ID: 32202790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020).
    Mehta CC; Bhatt HG
    Expert Opin Ther Pat; 2021 Jul; 31(7):645-661. PubMed ID: 33567917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and structural analysis of adenosine site binding tankyrase inhibitors.
    Haikarainen T; Waaler J; Ignatev A; Nkizinkiko Y; Venkannagari H; Obaji E; Krauss S; Lehtiö L
    Bioorg Med Chem Lett; 2016 Jan; 26(2):328-333. PubMed ID: 26706174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.
    Haikarainen T; Narwal M; Joensuu P; Lehtiö L
    ACS Med Chem Lett; 2014 Jan; 5(1):18-22. PubMed ID: 24900770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.